Hana Biosciences’ clinical trial agreement with the National Cancer Institute

Hana Biosciences’ clinical trial agreement with the National Cancer Institute

Hana Biosciences (OTCBB:HNAB) announced a Clinical Trial Agreement with the Center for Cancer Research (CCR) at the National Cancer Institute for the co-development of Marqibo(R) (vincristine sulfate liposomes injection) in refractory pediatric cancer. The five-year agreement will initially focus on a Phase 1 trial to evaluate the safety, preliminary efficacy, pharmacokinetic profile, and weekly dose of Marqibo in children and adolescents with refractory cancer. Following the Phase I trial, the Company and CCR plan a Phase 2 trial in pediatric acute lymphoblastic leukemia, the most common cancer of childhood. The Company anticipates that this Phase 2 trial will facilitate subsequent studies of Marqibo in combination with standard chemotherapy regimens.

Read the release.

Filed under: Business of Biotech, ,